Placental transfer of drugs and fetal risks

Paediatric and Perinatal Drug Therapy

Volumn 3, Issue 1, 1999, Pages 36-43

  Jacqz Aigrain, Evelyne ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Fetus; Malformation; Placenta; Pregnancy; Therapy; Toxicity

Indexed keywords

19 NORSTEROID; ALCOHOL; ANALGESIC AGENT; ANDROGEN; ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CURARE DERIVATIVE; CYCLOPHOSPHAMIDE; DIGITALIS; DIURETIC AGENT; ETRETIN; ISOTRETINOIN; LITHIUM; MERCAPTOPURINE; METHOTREXATE; TERATOGENIC AGENT; THALIDOMIDE; VALPROIC ACID; WARFARIN;

ARTICLE; BLOOD PLACENTA BARRIER; DRUG CLASSIFICATION; FETUS; FETUS RISK; HUMAN; PLACENTAL TRANSFER; PREGNANCY; TREATMENT INDICATION;

EID: 0032693917     PISSN: 14630095     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Pacifici GM, Nottoli R. Placental transfer of drugs administered to the mother. Clin Pharmacokinet 1995; 28: 235-269.
2. Abouleish E Jr, Wingard LB, de la Vega S. Pancuronium in caesarean section and its placental transfert. Br J Anaesth 1980; 52: 531-536.
3. Nau H, Plonait SL. Physicochemical and structural properties regulating placental transfert of drugs. In Polin and Fox (Eds): Fetal and neonatal physiology. WB Saunders, 2nd edn, 1988, pp. 146-160.
4. Kaufmann P, Schellen I. Placental development. In Polin and Fox (Eds): Fetal and neonatal physiology. WB Saunders, 3rd edn, 1992, pp. 47-56.
5. Metcalfe J, Bakke OM, Johannessen KH, Lund T. Estimation of uterine blood flow in human normal pregnancy at term. J Clin Invest 1955; 34: 1632-1638.
6. Lewandowski M, Hodgson E. Partial purification and characterization of cytochrome P450 from human placenta. Int J Biochem 1985; 17: 1149-1153.
7. Kellis JT, Vickery LE. Purification and characterization of human placental aromatase cytochrome P-450. J Biol Chem 1987; 262: 4413-4420.
8. Manchester DK, Parker NB, Bowman CM. Maternal smoking increases xenobiotic metabolism in placenta but not in umbilical vein endothelium. Pediatr Res 1984; 18: 1071-1075.
9. Schuetz JD, Kauma S, Guzelian PS. Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta. J Clin Invest 1993; 92: 1018-1024.
10. McRobbie DJ, Glover DD, Tracy TS. Regiospecificity of placental metabolism by cytochromes P450 and glutathione S-transferase. Gynecol Obstet Invest 1996; 42: 145-148.
11. Mattison DR, Malek A, Cistola C. Physiologic adaptations to pregnancy: impact on pharmacokinetics. In Yaffe-Aranda (Ed.): Pediatric Pharmacology - Therapeutic Principles in Practice. W.B. Saunders, 2nd edn, 1993, pp. 81-96.
12. Leiser R, Kaufmann P. Placental structure: in a comparative aspect. Exp Clin Endocrinol 1994; 102: 122-134.
13. Bourget P, Roulot C, Fernandez H. Transfert placentaire et métabolisme foeto-placentaire des médicame'nts: méthodes d'étude, apports et implications thérapeutiques. Thérapie 1994; 49: 481-497.
14. Bourget P, Fernandez H, Demirdjian S. Détermination des rapports de concentration sériques foeto-maternelles de la tobramycine à la naissance. Un modèle de pharmacocinétique réduite. Arch Fr Pédiatr 1991; 48: 543-547.
15. Good RG, Johnson GH. The placental transfer of kanamycin during late pregnancy Obstet gynecol 1971; 38: 60-62.
16. Stewart KS, Shafi M, Andrews J, Williams JD. Distribution of parenteral ampicillin and cephalosporins in late pregnancy. J Obstet Gynecol 1973; 80: 902-908.
17. Yoshioka H, Monma T, Matsuda S. Placental transfer of gentamicin.Pediatr Pharmacol 1972; 80: 121-123.
18. Forestier F, Daffos F, Rainaut M, Desnottes JF, Gaschard JC. Suivi thérapeutique foeto-maternel de la spiramycine au cours de la grossesse. Arch Fr Pediatr 1987; 44: 539-544.
19. Dorangeon PH, Ray R, Max-Chemla C, Leroux B, Harika G, Dupouy D, Quereux C, Choisy H, Pinon JM, Wahl P. Passage transplacentaire de l'association pyriméthamine - sulfadoxine lors du traitement antenatal de la toxoplasmose congénitale. Presse Med 1990; 19: 2036.
20. Fletcher CV. The placental transport and use of acyclovir in pregnancy. J Lab Clin Med 1992, pp. 821-822.
21. Gilstrap LC, Bawdon RE, Roberts SW, Sobhi S. The transfer of the nucleoside analog ganciclovir accross the perfused human placenta. Am J Obstet Gynecol 1994; 170: 967-973.
22. IshizakiT, Yokochi K, Chiba K, Tabuchi T, Wagatsuma T. Placental transfer of anticonvulsivants (phenobarbital, phenytoin and valproic acid) and the elimination from neonates. Pediatr Pharmacol 1981; 1: 291-303.
23. Nau H, Kuhnz W, Egger HJ, Rating D, Helge H. Anticonvulsivants during pregnancy and lactation. Transplacental maternal and neonatal pharmacokinetics. Clin Pharmacokinet 1982; 7: 508-543.
24. Mandelli M, Morselli PL, Nordio S, Pardi G, Principi N, Sereni F, Tognoni G. Placental transfer of diazepam: its disposition in the newborn. Clin Pharmacol Ther 1975; 17: 564-572.
25. Spencer MJ. Fluoxetine hydrochloride (prozac) toxicity in a neonate. Pediatrics 1993; 92: 721-722.
26. Mijanna MJ, Bennett JB, Izatt SD. Potential fluoxetine chloride (prozac) toxicity in a newborn. Pediatrics 1997; 100(1): 158-159.
27. Lupoglazoff JM, Jacqz Aigrain E, Guyot B, Chappey O, Blot P. Endogenous digoxin-like immunoreactivity during pregnancy and a birth. Br J Clin Pharmac 1993; 35: 251-254.
28. Younis JS, Granat M. Insufficient transplacental digoxin transfer in severe hydrops fetalis. Am J Obstet Gynecol 1987; 157: 1268-1269.
29. Yurth DA. Placental transfer of local anesthetics. Clin Perinat 1982; 9: 13-28.
30. Levitz M, Jansen V, Dancis J. The transfer and metabolism of corticosteroids in the perfused human placenta. Am J Obstet Gynecol 1978; 132: 363-366.
31. Blanford AT, Murphy BEP. In vitro metabolism of prednisolone, dexamethasone, betamethasone and cortisol by the human placenta. Am J Obstet Gynecol 1977; 127: 264-267.
32. Beitins IZ, Bayard F, Ances IG, Kowarski A, Migeon CJ. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr 1972; 81: 936-945.
33. Osathanondh R, Tulchinsky YD, Kamali H, Fencl MM, Taeusch HW. Dexamethasone levels in treated pregnant women and newborn infants. J Pediatr 1977; 90: 617-620.
34. Smithells RW. Defects and disabilities of thalidomide children. Br Med J 1973; 1: 269-272.
35. Rosa FW, Wilk AL, Kelssey FO. Teratogen update: vitamin A congeners. Teratology 1986; 33: 355-364.
36. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet 1982; ii: 937.
37. Jäger-Roman E, Deichl A, Jakob S, Hartmann AM, Koch S, Rating D, Steldinger R, Nau H, Helge H. Fetal growth, major malformations and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986; 108: 997-1004.
38. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68: 122-140.
39. Ebert U, Loffler H, Kirch. Cytotoxic therapy and pregnancy. Pharmacol Ther 1997; 74: 207-220.
40. Green DM, Fiorello A, Zevon MA, Hall B, Seigelstein N. Birth defects and childhood cancer in offspring of survivors of childhood cancer. Arch Pediatr Adolesc Med 1997; 151: 379-383.
41. Schardein JL. Congenital abnormalities and hormones during pregnancy: a clinical review. Teratology 1980; 22: 251-270.
42. Miller MS, Juchau MR, Guengerich FP, Nebert DW, Raucy JL. Drug metabolic enzymes in developmental toxicology. Fund Appl Toxicol 1996; 34: 164-175.
43. Spielberg SP. Pharmacogenetics and the fetus. N Engl J Med 1982; 307: 115-116.
44. Jones KL, Smith DW, Ulleland CN, Streissguth AP. Pattern of malformation in offspring of chronic alcoholic mothers. Lancet 1973; i: 1267-1271.
45. Quelette EM, Rosett HL, Rosman NP, Weiner L. Adverse effects on offspring of maternal alcohol abuse during pregnancy. N Engl J Med 1977; 297: 528-530.
46. Carpenter SP, Lasker JM, Raucy JL. Expression, induction and catalytic activity of the ethanol cytochrome P450 (CYP2E1) in human fetal liver and hepatocytes. Mol Pharmacol 1998; 49: 260-268.
47. Steward DJ. The effects of tetracyclines upon dentition. Br J Dermatol 1964; 76: 374-378.
48. Gilbert T, Lelievre-Pegorier M, Merlet-Benichou C. Immediate and long-term renal effects of fetal exposure to gentamicin. Pediatr Nephrol 1990; 4: 445-450.
49. Kleinman CS, Copel JA, Weinstein EM, Santulli TV Jr, Hobbins JC. Treatment of fetal supraventricular arrhythmias. J Clin Ultrasound 1985; 13: 365-373
50. Fermont L. Recherche, identification, pronostic et traitement des troubles du rythme et de la conduction chez le foetus. In Doin (Ed): Troubles du rythme cardiaque chez l'enfant. 1987, Paris, pp. 37-54.
51. Azancot-Benisty A, Jacqz-Aigrain E, Guirguis NM, de Crepy A, Oury JF, Blot P. Clinical and pharmacological study of fetal supraventricular tachyarrhythmias. J Pediatr 1992; 121: 608-613.
52. Saarikoski S. Placental transfer and fetal uptake of 3H-digoxin in humans. Br J Obstet Gynaecol 1976; 83: 879-884.
53. Allan LD, Chita SK, Sharland GK, Maxwell D, Priestley K. Flecainide in the treatment of fetal tachycardias. Br Heart J 1991; 65: 46-48.
54. Bourget P, Pons JC, Delouis C, Fermont L, Frydman R. Flecainide distribution, transplacental passage and accumulation in the amniotic fluid during the third trimester of pregnancy. Ann Pharmacother 1994; 28: 1031-1034.
55. Lacaze Masmonteil T. Corticothérapie antenatale et accélération de la maturation foetale. Données expérimentales et pharmacologiques. Arch Pediatr 1996; 3: 1111-1117.
56. Ballard PL, Granberg P, Ballard RA. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome. J Clin Invest 1975; 56: 1548-1554.
57. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972; 50: 515-525.
58. Hanssens M, Keirse MJNC, Vankelecom F, VanAssche FA. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 1991; 78: 128-135.
59. Lip GYH, Churchill D, Beevers M, Auckett A, Beevers DG. Angiotensin-converting-enzyme inhibitors in early pregnancy. Lancet 1997; 350: 1446-1447.
60. Bavoux F. Toxicité foetale des anti-inflammatoires non stéroïdiens. Presse Méd 1992; 21(40): 1909-1912.
61. Dawood MY. Nonsteroidal antiinflammatory drugs and reproduction. Am J Obstet Gynecol 1993; 169: 1255-1265.
62. Rubin PC. Medical intelligence (current concepts). Beta-blockers in pregnancy. N Engl J Med 1981; 305(22): 1323-1326.
63. Little BB, VanBeveren TT. Placental transfer of selected subtances of abuse. Seminars in Perinatology 1996; 20: 147-153.
64. Schenker S, Yang Y, Johnson RF, Downing JW, Sehenden RS, Henderson GI, King TS. The transfer of cocaine and its metabolites accross the term human placenta. Clin Pharmacol Ther 1993; 53: 329-339.
65. Simone C, Derewlany LO, Oskamp M, Knie B, Koren G. Transfer of cocaine and benzoylecgonine accross the perfused human placental cotyledon. Am J Obstet Gynecol 1994; 170: 1404-1410.
66. Fisher SE, Atkinson M, Chang B. Effect of delta-9-tetrahydrocannabinol on the in vitro uptake of alpha-aminoisobutyric acid by term human placenta. Pediatr Res 1987; 21: 104-107.
67. Rosen TS, Pippenger CE. Disposition of methadone and its relation to severity of withdrawal in the newborn. Addictive Dis 1975; 2: 169-178.
68. Day NL, Cottreau CN, Richardson GA. The epidemiology of alcohol, marijuana and cocaine use among women of childbearing age and pregnant women. Clin Obstet Gynecol 1993; 36: 232-245.